Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody

Clinical Cancer Research

Volumn 17, Issue 8, 2011, Pages 2270-2280

  Fransen, Marieke F ^a   Sluijter, Marjolein ^a   Morreau, Hans ^a   Arens, Ramon ^a   Melief, Cornelis J M ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ISA Pharmaceuticals   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD40 LIGAND MONOCLONAL ANTIBODY; MONTANIDE ISA 51;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; INGUINAL LYMPH NODE; LOCAL THERAPY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; T LYMPHOCYTE ACTIVATION; TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; MALE; MANNITOL; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLEIC ACIDS; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 79954579274     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2888     Document Type: Article

References (40)

1. Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell 1986;44:959-68. (Pubitemid 16045342)
2. Boon T, De PE, Lurquin C, Van den Eynde B, van der Bruggen P, Traversari C, et al. Identification of tumour rejection antigens recognized by T lymphocytes. Cancer Surv 1992;13:23-37.
3. Van PA, Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A 1982;79:4718-22.
4. Gilboa E. The makings of a tumor rejection antigen. Immunity 1999;11:263-70. (Pubitemid 29463234)
5. Fuchs EJ, Matzinger P. Is cancer dangerous to the immune system? Semin Immunol 1996;8:271-80. (Pubitemid 26413867)
6. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994;12:991-1045. (Pubitemid 24140436)
7. Nguyen LT, Elford AR, Murakami K, Garza KM, Schoenberger SP, Odermatt B, et al. Tumor growth enhances cross-presentation leading to limited T cell activation without tolerance. J Exp Med 2002;195:423-35. (Pubitemid 34461296)
8. Melief CJ, Toes RE, Medema JP, Van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000;75:235-82. (Pubitemid 30436846)
9. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-35. (Pubitemid 28183361)
10. van Mierlo GJ, den Boer AT, Medema JP, van der Voort EI, Fransen MF, Offringa R, et al. CD40 stimulation leads to effective therapy of CD40 (-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A 2002;99:5561-6. (Pubitemid 34411588)
11. Todryk SM, Tutt AL, Green MH, Smallwood JA, Halanek N, Dalgleish AG, et al. CD40 ligation for immunotherapy of solid tumours. J Immunol Methods 2001;248:139-47. (Pubitemid 32167031)
12. Broomfield SA, Van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, et al. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol 2009;182:5217-24.
13. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490-6. (Pubitemid 36951021)
14. Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, et al. Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A 2009;106:19455-60.
15. Zhang M, Yao Z, Dubois S, Ju W, Muller JR, Waldmann TA. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A 2009;106:7513-8.
16. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, et al. Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol 1999;162:5838-45. (Pubitemid 29314936)
17. Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003;102:1449-57. (Pubitemid 36988056)
18. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870, 893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007;25:876-83. (Pubitemid 350002889)
19. Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009;15:169-73.
20. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28. (Pubitemid 44343545)
21. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23:6043-53.
22. + CTL to cause tumor eradication. J Immunol 2004;173:6753-9. (Pubitemid 39541061)
23. Hargadon KM, Brinkman CC, Sheasley-O'neill SL, Nichols LA, Bullock TN, Engelhard VH. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes. J Immunol 2006;177:6081-90. (Pubitemid 44628823)
24. Toes RE, Blom RJ, van d V, Offringa R, Melief CJ, Kast WM. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells. Cancer Res 1996;56:3782-7. (Pubitemid 26272029)
25. Moore MW, Carbone FR, Bevan MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988;54:777-85.
26. Rolink A, Melchers F, Andersson J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 1996;5:319-30. (Pubitemid 26366755)
27. Johansen P, Corradin G, Merkle HP, Gander B. Release of tetanus toxoid from adjuvants and PLGA microspheres: how experimental set-up and surface adsorption fool the pattern. J Control Release 1998;56:209-17. (Pubitemid 28511141)
28. Lorentz K, Flatter B. Clinical application of a new method for the determination of aminoacylase in human serum. Clin Chim Acta 1975;63:271-4.
29. Taraban VY, Rowley TF, Al-Shamkhani A. Cutting edge: a critical role for CD70 in CD8 T cell priming by CD40-licensed APCs. J Immunol 2004;173:6542-6. (Pubitemid 39541037)
30. Sanchez PJ, McWilliams JA, Haluszczak C, Yagita H, Kedl RM. Combined TLR/CD40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of CD70 in vivo. J Immunol 2007;178:1564-72. (Pubitemid 46154627)
31. French RR, Taraban VY, Crowther GR, Rowley TF, Gray JC, Johnson PW, et al. Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation. Blood 2007;109:4810-5. (Pubitemid 46827776)
32. + T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007;13:354-60. (Pubitemid 46376686)
33. Kedl RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S. CD40 stimulation accelerates deletion of tumor-specific CD8 (+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A 2001;98:10811-6. (Pubitemid 32878702)
34. Liu XY, Pop LM, Vitetta ES. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008;222:9-27. (Pubitemid 351430363)
35. Tuve S, Chen BM, Liu Y, Cheng TL, Touré P, Sow PS, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007;67:5929-39. (Pubitemid 46985029)
36. Simmons AD, Moskalenko M, Creson J, Fang J, Yi S, Van Roey MJ, et al. Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother 2008;57:1263-70.
37. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010;10:317-27.
38. Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, et al. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 2008;20:1467-79.
39. Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, et al. Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 2008;111:3116-25.
40. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.